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Programmed death 1 (PD-1) and programmed death-ligand 1 (PD-L1) pathway have now 
attracted increasing attention because many studies have demonstrated that positive PD-L1 
expression was correlated with favourable clinical benefits achieved with anti–PD-1/PD-L1 
antibodies. However, the prognostic impact of PD-L1 expression itself remains controversial, 
and the presence of PD-L1 positivity in cohorts of patients has been reported to be related 
from a poor prognosis to better locoregional control and prognosis. Briefly, tumor cells that 
express PD-L1 may survive immune regulation by binding to PD-1 on CD8+ cytotoxic T cells 
(CTLs) thereby downregulating CTL function, which otherwise would have attacked and 
killed the tumor cells. Thus, the PD-1/PD-L1 pathway shows their effects by interaction 
with the surrounding immune microenvironment. Moreover, cancer immunity itself consists 
of various immune cells. So far, few studies have evaluated the relationship between 
PD-1/PD-L1 pathway and the surrounding immune microenvironment. We hypothesized 
that the prognostic impact of the PD-1/PD-L1 pathway may be affected by the status of other 
biological factors involved in cancer immunity, such as CD4, CD8, regulatory T cells (Tregs) 
and human leukocyte antigen (HLA) class I molecules, which have critical roles in cancer 
immunity as well. Therefore, we conducted this translational study. 
We retrospectively reviewed 126 patients with pathologic stage I non-small cell lung cancer 
who underwent complete resection without induction therapy between April 2013 and 
December 2015. PD-L1 expression was evaluated with immunohistochemistry in correlation 
with clinicopathologic features and surrounding immune microenvironment status, 
including CD4, CD8, Tregs and HLA class I. Factors affecting prognosis were assessed by 
the Kaplan–Meier method and Cox regression analyses. 
Analysis of 126 lung cancer patients revealed that positive PD-L1 expression status on 
tumor cells was a potential factor to predict poor prognosis, which may depend on 
concurrent CD8 status, especially existing in the intratumoral compartment in lung cancer. 
A total of 23 patients (18.3%) were positive for PD-L1 expression. No significant correlation 
was observed between PD-L1 expression and the surrounding immune microenvironment 
status. The PD-L1–positive group had a worse prognosis than the PD-L1–negative group 
(5-year recurrence-free survival [RFS] rates, 63.4% vs. 81.0%; P=0.061). Among surrounding 
immune cells, intratumoral CD8 status had an impact on prognosis most strongly (P=0.12). 
In the intratumoral CD8–high group, PD-L1 expression demonstrated no significant 
prognostic impact, whereas in the intratumoral CD8–low group, patients positive for PD-L1 
demonstrated a significantly worse prognosis than those negative for PD-L1 (5-year RFS 
rates, 41.7% vs. 78.6%; P=0.034). Multivariable Cox regression analysis revealed that 
‘PD-L1–positive and intratumoral CD8–low’ status was an independent prognostic factor 
(hazard ratio, 3.80; 95% confidence interval, 1.22–10.5; P=0.023). 
We concluded that the prognostic impact of the PD-1/PD-L1 pathway may be distinct 
according to concurrent intratumoral CD8 status. 
 
